Peptide Guide + Calculator
Tirzepatide Reconstitution Calculator & Guide
GLP-1 / GIP Dual Receptor Agonist
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in FDA-approved prescription products for type 2 diabetes, chronic weight management, and certain adults with obesity and obstructive sleep apnea. This page explains how Tirzepatide works, clinical-trial evidence, comparisons with Semaglutide and Retatrutide, common safety considerations, and educational reconstitution math.
Evidence Snapshot
Tirzepatide research at a glance
Standardized regulatory and evidence context so research compounds, investigational drugs, and approved medications are not treated as if they have the same level of human evidence.
Primary mechanism
Dual GIP and GLP-1 receptor agonist.
WADA context
No specific prohibition identifiedHuman intervention evidence
Large Phase 3 SURPASS and SURMOUNT programs support FDA-approved Mounjaro and Zepbound products and multiple indications.
Human biology evidence
Extensive human metabolic and incretin pharmacology with large clinical-development programs in diabetes, obesity, sleep apnea, and cardiovascular outcomes.
Key takeaway
A dual-incretin therapy with regulatory-grade evidence and a useful comparator for both semaglutide and investigational retatrutide.
Evidence labels describe the research base and regulatory context; they are not treatment, dosing, or use recommendations. Review dates describe the last BACToBasics source check for this evidence summary. Anti-doping rules can change and should be verified with the applicable authority.
Tirzepatide Reconstitution Calculator
Enter the vial amount, liquid volume, and amount you want to calculate. BACToBasics will automatically calculate concentration, liquid volume, and U-100 syringe-unit equivalents.
Loading calculator...
Calculator values are educational math inputs only. They are not recommended preparation amounts, doses, or use protocols.
Tirzepatide Reconstitution Math
Reconstitution math starts with the amount contained in the vial and the liquid volume used in the calculation. Dividing the vial amount by the liquid volume gives the resulting concentration.
Example vial amount
10 mg
| Liquid Volume | Calculation | Concentration |
|---|---|---|
| 1 mL | 10 mg ÷ 1 mL | 10 mg/mL |
| 2 mL | 10 mg ÷ 2 mL | 5 mg/mL |
| 3 mL | 10 mg ÷ 3 mL | 3.3333 mg/mL |
This table demonstrates concentration math only. The liquid volumes shown are examples for comparison and are not preparation recommendations.
More Reconstitution Tools
Need to compare different liquid volumes or convert between mg, mcg, mL, and U-100 units? Use the dedicated BACToBasics calculator tools.
What is Tirzepatide?
Tirzepatide is a medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It was developed by Eli Lilly and is the active ingredient in the prescription products Mounjaro and Zepbound. Its effects on glucose regulation, appetite, satiety, and body weight have made it one of the most widely studied incretin-based medications.
How does Tirzepatide work?
Tirzepatide activates two incretin hormone receptors: GIP and GLP-1. These pathways are involved in insulin secretion, glucagon regulation, appetite, food intake, and metabolic signaling. The combination of GIP and GLP-1 receptor activity distinguishes Tirzepatide from medications such as Semaglutide that primarily target GLP-1 receptors.
Mounjaro vs Zepbound
Mounjaro and Zepbound contain the same active ingredient, Tirzepatide, but are FDA-approved and marketed for different indications. Mounjaro was approved to improve glycemic control in adults with type 2 diabetes in addition to diet and exercise. Zepbound was approved for chronic weight management in qualifying adults with obesity or overweight and later received an additional approval for moderate-to-severe obstructive sleep apnea in adults with obesity.
Tirzepatide for weight loss
Tirzepatide has produced substantial average weight reductions in randomized clinical trials. In the Phase 3 SURMOUNT-1 trial involving adults with obesity or overweight without diabetes, average weight reduction at 72 weeks ranged from approximately 15% with the 5mg treatment group to approximately 20.9% with the 15mg group, compared with about 3.1% with placebo. Individual results vary, and clinical-trial averages should not be interpreted as predictions for a particular person.
Tirzepatide vs Semaglutide
Semaglutide primarily activates GLP-1 receptors, while Tirzepatide activates both GIP and GLP-1 receptors. In the Phase 3b SURMOUNT-5 trial in adults with obesity without type 2 diabetes, Tirzepatide produced greater average reductions in body weight and waist circumference than Semaglutide at 72 weeks. The medications have different approved products, indications, dosing regimens, and individual response profiles.
Tirzepatide vs Retatrutide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, while Retatrutide is an investigational triple agonist that also activates the glucagon receptor. Tirzepatide is already available in FDA-approved prescription products, while Retatrutide remains investigational as of 2026. The additional glucagon-receptor activity is the major mechanistic distinction between them.
Tirzepatide and appetite
Reduced appetite, increased fullness, and lower food intake are commonly observed with Tirzepatide. These effects contribute to weight reduction, although the medication also influences multiple metabolic and glucose-regulatory pathways. Appetite response and weight change vary significantly between individuals.
Tirzepatide and type 2 diabetes
Tirzepatide was first approved in the United States under the brand name Mounjaro to improve glycemic control in adults with type 2 diabetes in addition to diet and exercise. Clinical trials have demonstrated substantial reductions in glycated hemoglobin as well as body weight in many participants with type 2 diabetes.
Tirzepatide and cardiovascular outcomes
The large SURPASS-CVOT trial evaluated Tirzepatide against Dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide was noninferior to Dulaglutide for the composite outcome of cardiovascular death, myocardial infarction, or stroke. The trial did not establish statistical superiority for that primary cardiovascular outcome.
Tirzepatide and obstructive sleep apnea
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first medication approved for this specific indication. Clinical studies showed reductions in apnea-hypopnea events and improvements in body weight compared with placebo.
Common Tirzepatide side effects
The most frequently reported adverse effects are gastrointestinal. These include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and decreased appetite. Gastrointestinal effects are particularly common during periods when exposure is being increased in clinical treatment.
Important Tirzepatide safety considerations
FDA-approved Tirzepatide products carry important warnings and precautions. These include risks involving pancreatitis, gallbladder disease, hypoglycemia when combined with certain diabetes medications, kidney problems related to severe gastrointestinal symptoms or dehydration, and other complications. Tirzepatide prescribing information also includes a boxed warning related to thyroid C-cell tumors observed in rats; the relevance of this finding to humans is unknown.
Tirzepatide and thyroid C-cell tumors
FDA-approved Tirzepatide labeling includes a boxed warning because Tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether Tirzepatide causes medullary thyroid carcinoma or other thyroid C-cell tumors in humans. Prescription labeling lists a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 as contraindications.
Compounded or research Tirzepatide vs FDA-approved Tirzepatide
Mounjaro and Zepbound are FDA-approved Tirzepatide products manufactured under regulated pharmaceutical standards. Products advertised as compounded or research Tirzepatide should not automatically be assumed to have the same formulation, concentration, purity, sterility, quality controls, or regulatory status as an FDA-approved product.
Tirzepatide reconstitution math
Reconstitution calculations depend on the labeled amount in a vial and the liquid volume used. As a mathematical example, a 10mg vial combined with 2mL of liquid produces a concentration of 5mg per mL. BACToBasics uses these examples only to demonstrate concentration, liquid-volume, and U-100 syringe-unit conversions rather than to provide dosing or preparation instructions.
Explore more about Tirzepatide
14 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Explore more about Tirzepatide
14 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Compare Tirzepatide
Direct comparison pages are selected from the indexable BACToBasics comparison catalog and update automatically as that catalog grows.
Cagrilintide vs Tirzepatide
Compare Cagrilintide, Tirzepatide using the same evidence dataset.
Open →
ComparisonCagriSema vs Tirzepatide
Compare CagriSema, Tirzepatide using the same evidence dataset.
Open →
ComparisonMariTide vs Tirzepatide
Compare MariTide, Tirzepatide using the same evidence dataset.
Open →
ComparisonSemaglutide vs Tirzepatide
Compare Semaglutide, Tirzepatide using the same evidence dataset.
Open →
Research, updates & development
Jump from the guide into the public update timeline, compound-specific research records, and clinical-development tracker without searching again.
Tirzepatide research & development updates
Open the public timeline of sourced research records and material development changes tracked by BACToBasics.
Open →
ResearchTirzepatide research sources
Open 2 curated research records for Tirzepatide.
Open →
DevelopmentTirzepatide clinical development
Approved · Approved. Mounjaro and Zepbound are FDA-approved products.
Open →
Related peptide guides
Related guides are ranked from shared comparison pages, shared blend pages, and peptide category rather than a hand-maintained link list.
Semaglutide guide & calculator
Metabolic & Weight Loss · GLP-1 Receptor Agonist
Open →
Peptide guideRetatrutide guide & calculator
Metabolic & Weight Loss · GLP-1 / GIP / Glucagon Triple Receptor Agonist
Open →
Peptide guideAOD-9604 guide & calculator
Metabolic & Weight Loss · Modified Human Growth Hormone Fragment
Open →
Peptide guideCagrilintide guide & calculator
Metabolic & Weight Loss · Long-Acting Amylin Analog
Open →
Relevant glossary concepts
Definitions are matched against the guide's structured title, subtitle, description, and educational sections.
FDA-Approved
A status indicating that the FDA has approved a specific drug product for one or more labeled uses after reviewing the required evidence and manufacturing information.
Open →
GlossaryMilliliter (mL)
A metric unit of liquid volume equal to one-thousandth of a liter.
Open →
GlossaryAgonist
A molecule that binds to a receptor and activates signaling through that receptor.
Open →
Tirzepatide FAQ
Tap a question to expand only the answer you want to read.
Is Tirzepatide FDA-approved?
Yes. Tirzepatide is the active ingredient in FDA-approved prescription products. Mounjaro is approved for improving glycemic control in adults with type 2 diabetes, while Zepbound is approved for chronic weight management in qualifying adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.
What is the difference between Mounjaro and Zepbound?
Both contain Tirzepatide. They are marketed under different brand names and have different FDA-approved indications. Mounjaro is associated with type 2 diabetes treatment, while Zepbound is approved for chronic weight management and certain adults with obesity and obstructive sleep apnea.
Does Tirzepatide reduce appetite?
Yes. Reduced appetite, increased fullness, and lower food intake are commonly observed effects of Tirzepatide and contribute to its effects on body weight.
How much weight loss has Tirzepatide shown in clinical trials?
In the SURMOUNT-1 trial, average weight reduction after 72 weeks ranged from approximately 15% to 20.9% across the Tirzepatide treatment groups, compared with approximately 3.1% with placebo. Results vary by dose, study population, treatment duration, and individual response.
Is Tirzepatide better than Semaglutide for weight loss?
In the head-to-head SURMOUNT-5 clinical trial in adults with obesity without diabetes, Tirzepatide produced greater average reductions in body weight and waist circumference than Semaglutide at 72 weeks. This trial result does not mean every individual will respond better to Tirzepatide.
How is Tirzepatide different from Semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors, while Semaglutide primarily activates GLP-1 receptors.
How is Tirzepatide different from Retatrutide?
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1, and glucagon receptors. Tirzepatide is available in FDA-approved prescription products, while Retatrutide remains investigational as of 2026.
What are the most common Tirzepatide side effects?
Common adverse effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and decreased appetite. The frequency and severity vary between individuals.
Can Tirzepatide cause pancreatitis?
Pancreatitis is included among the important warnings and precautions for FDA-approved Tirzepatide products. Anyone using prescription Tirzepatide should follow the prescribing clinician's guidance regarding concerning symptoms and adverse effects.
Does Tirzepatide have a thyroid cancer warning?
FDA-approved Tirzepatide products include a boxed warning because thyroid C-cell tumors occurred in rats. It is unknown whether Tirzepatide causes these tumors in humans. The prescribing information includes contraindications involving a personal or family history of medullary thyroid carcinoma or MEN 2.
Is Tirzepatide approved for sleep apnea?
Yes. Zepbound was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.
Does Tirzepatide reduce cardiovascular risk?
In the SURPASS-CVOT trial involving people with type 2 diabetes and established cardiovascular disease, Tirzepatide was noninferior to Dulaglutide for major cardiovascular events. The primary analysis did not establish superiority.
Is compounded Tirzepatide the same as Mounjaro or Zepbound?
It should not automatically be considered equivalent. FDA-approved Mounjaro and Zepbound are manufactured as regulated pharmaceutical products, while compounded or research products may differ in formulation, manufacturing controls, concentration, quality, and regulatory status.
How do you calculate Tirzepatide reconstitution concentration?
Divide the labeled amount in the vial by the liquid volume. For example, 10mg divided by 2mL equals 5mg per mL. This is mathematical concentration conversion rather than a recommendation for how Tirzepatide should be prepared.
Can the BACToBasics calculator handle Tirzepatide math?
Yes. Enter a labeled vial amount and liquid volume to calculate concentration, equivalent liquid volume, U-100 syringe units, and approximate amounts per vial. BACToBasics provides educational math rather than medical or dosing advice.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
FDA announcement covering the 2023 approval of Tirzepatide under the Zepbound brand for chronic weight management in qualifying adults.
FDA announcement covering the December 2024 approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
FDA information covering the 2022 approval of Tirzepatide under the Mounjaro brand for improving glycemic control in adults with type 2 diabetes.
Peer-reviewed SURMOUNT-1 Phase 3 trial evaluating Tirzepatide for obesity over 72 weeks. DOI: 10.1056/NEJMoa2206038.
Peer-reviewed SURMOUNT-5 head-to-head trial comparing Tirzepatide with Semaglutide in adults with obesity without type 2 diabetes. DOI: 10.1056/NEJMoa2416394.
Peer-reviewed SURPASS-CVOT trial evaluating major cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease. DOI: 10.1056/NEJMoa2505928.
BACToBasics provides educational information and math tools only. This content is not medical advice, dosing advice, injection instruction, or a recommendation to use any peptide or medication.